Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 4, 2000, Pages 422-430

  Itoh, Takashi ^a   Hayashi, Yoshitake ^a   Kanamaru, Taichi ^a   Morita, Yasushi ^a   Suzuki, Satoshi ^a   Wang, Weiping ^a   Zhou, Li ^b   Rui, Jing An ^c   Yamamoto, Masahiro ^a   Kuroda, Yoshikazu ^a   Itoh, Hiroshi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Beijing General Post & Telecom Hospital   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Hepatocellular carcinoma; Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 2; Recurrence; Urokinase type plasminogen activator

Indexed keywords

ALPHA FETOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER RESECTION; MALE; METASTASIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SURVIVAL RATE; WESTERN BLOTTING;

EID: 0034016264     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02150.x     Document Type: Article

References (50)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
2. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 1985; 44: 139-266.
3. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993; 73: 161-95.
4. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 1990; 111: 783-92.
5. Conesi M, Blasi F. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol. Chem. Hoppe-Seyler 1995; 376: 143-55.
6. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic maker in breast cancer. Cancer Res. 1990; 50: 6827-9.
7. Sier CFM, Verspaget HW, Griffioen G et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology 1991; 101: 1522-8.
8. De Bruin PAF, Griffioen G, Verspaget HW et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 1988; 48: 4520-4.
9. Pendersen H, Grøndahl-Hansen J, Francis D et al. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res. 1994; 54: 120-3.
10. Grøndahl-Hansen J, Christensen IJ, Rosenquist C et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53: 2513-21.
11. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994; 54: 2900-7.
12. Penderson H, Brünner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994; 54: 4671-5.
13. Kobayashi H, Fujishiro S, Toshihiko T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994; 54: 6539-48.
14. Daneri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A et al. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur. J. Cancer 1998; 34: 566-9.
15. Foekens JA, Schmitt M, van Putten WLJ et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol. 1994; 12: 1648-58.
16. Knoop A, Andreasen PA, Andersen JA et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br. J. Cancer 1998; 77: 932-40.
17. Duggan C, Kennedy S, Kramer MD et al. Plasminogen activator inhibitor type 2 in breast cancer. Br. J. Cancer 1997; 76: 622-7.
18. Foekens JA, Buessecker F, Peters HA et al. Plasminogen activator inhibitor-2: Prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 1995; 55: 1423-7.
19. Ganesh S, Sier CFM, Heerding MM et al. Contribution of plasminogen activator and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br. J. Cancer 1997; 75: 1793-801.
20. Ganesh S, Sier CFM, Griffioen G et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 1994; 54: 4065-71.
21. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br. J. Cancer 1994; 69: 398-405.
22. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EK. Inhibition of invasion of HT-1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res. 1993; 53: 6051-7.
23. Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell line A549 and Calu-1. Cancer Res. 1992; 52: 3043-7.
24. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 1994; 54: 3066-71.
25. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Miniwa N, Terao T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer 1994; 57: 727-33.
26. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 1996; 134: 1563-71.
27. Itoh H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchow Arch. 1996; 427: 487-96.
28. Dufiy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lunen HJ. Urokinase-plasminogen activator, a marker for aggressive breast cancer. Cancer 1988; 62: 531-3.
29. Vauthey JN, Klimstra D, Franceschi D et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am. J. Surg. 1995; 169: 28-35.
30. Arii S, Tanaka J, Yamazoe Y et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992; 69: 913-19.
31. Morita Y, Hayashi Y, Wang Y et al. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology 1997; 25: 856-61.
32. Petro GD, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (uPA), uPA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998; 58: 2234-9.
33. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48 900 necropsies. Cancer 1954; 7: 462-503.
34. eRBB2 expression and the gene amplification. Cancer Res. 1990; 50: 8002-9.
35. Nagao T, Goto S, Kawano M et al. Hepatic resection for hepatocellular carcinoma. Ann. Surg. 1987; 205: 33-40.
36. Kanematsu T, Matsumata T, Takenaka K, Yoshida Y, Higashi H, Sugimachi K. Clinical management of recurrent hepatocellular carcinoma after primary resection. Br. J. Surg. 1988; 75: 203-6.
37. Yamasaki S, Makuuchi M, Hasegawa H. Results of hepatectomy for hepatocellular carcinoma at the National Cancer Center Hospital. HPB Surgery 1991, 14: 802-5.
38. Yamanaka N, Okamoto E, Toyosaka A et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990; 65: 1104-10.
39. Belghti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann. Surg. 1991; 214: 114-17.
40. Okada S, Shimada K, Yamamoto J et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106: 1618-24.
41. Wei Y, Waltz DA; Rao N et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 1994; 269: 32 380-8.
42. Nip J, Rabbani SA, Shibata HR et al. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator in metastatic melanoma cells. J. Clin. Invest. 1994; 95: 2096-103.
43. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5.
44. Xue W, Mizutani I, Todd RF et al. Urokinase-type plasminogen activator receptors associate with b1 and b3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res. 1997; 57: 1682-9.
45. Waltz DA, Natkin LR, Fujita RM et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 1997; 100: 58-67.
46. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsu O. Plasminogen activator inhibitor 1 in human carcinoma tissues. Int. J. Cancer 1991; 48: 481-4.
47. Goretzki L, Schmitt M, Mann K et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin. FEBS Lett. 1992; 297: 112-18.
48. Kobayasi H, Schmitt M, Goretzki L et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol. Chem. 1991; 266: 5147-52.
49. Bajou K, Noël A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 1998; 8: 923-8.
50. Ponton A, Coulombe B, Skuo D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res. 1991; 51: 2138-43.